SS Innovations International, Inc. has completed a private placement generating approximately $18.6 million in gross proceeds to support the company's growth initiatives in surgical robotics. The Nasdaq-listed company, which develops robotic technologies aimed at making robotic surgery more accessible globally, closed the financing on March 6, 2026.
The private placement involved the sale of 5,774,839 shares of common stock through two tranches. Company leadership including Chairman and CEO Dr. Sudhir Srivastava, Vice-Chairman Dr. Frederic H. Moll, and director Tim Adams purchased approximately $5.2 million worth of shares at an average price of $4.00 per share. Existing and new investors, led by existing shareholder Manipal Global Health Services, purchased approximately $13.4 million worth of shares at $3.00 per share.
According to the company, net proceeds will be used for working capital and general corporate purposes, with specific focus on advancing global expansion efforts. Dr. Srivastava stated that the financing will support growth initiatives in India and other existing markets while preparing for entry into United States and European Union markets.
The timing of this financing coincides with important regulatory milestones for the company's SSi Mantra surgical robotic system. Dr. Srivastava indicated that the U.S. Food and Drug Administration is expected to complete its review of the company's 510(k) premarket notification by mid-2026. The company also continues toward European Union CE marking certification, which it believes can be obtained in 2026.
Dr. Srivastava emphasized that insider participation in the financing reflects confidence in SS Innovations' future and commitment to democratizing access to surgical robotic care. The company's website at https://ssinnovations.com provides additional information about its technologies and mission.
The SSi Mantra system represents the company's approach to making robotic surgery more accessible through user-friendly, modular technology. The system features 3 to 5 modular robotic arms, an ergonomic surgeon command center, 3D 4K visualization, and compatibility with over 40 different types of robotic endo-surgical instruments. The system has been clinically validated in India across more than 100 different surgical procedures.
This financing represents a significant step for SS Innovations as it positions itself to compete in the global surgical robotics market. The involvement of company leadership and existing shareholders like Manipal Global Health Services signals confidence in the company's strategy and technology. As healthcare systems worldwide seek to expand access to advanced surgical technologies while controlling costs, SS Innovations' focus on affordability and accessibility could position it favorably in emerging markets and beyond.
The private placement securities were not registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or applicable exemption. The company's forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations.
